Clinical Trial Update: Trial to Evaluate Safety, Tolerability, and Parmacokinetics of ALN-TTR02 in Healthy Volunteer Subjects [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating safety, tolerability, and pharmacokinetics of ALN-TTR02 in healthy volunteers for transthyretin-mediated amyloidosis; study status is c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Transthyretin-mediated Amyloidosis

Drugs mentioned

• ALN-TTR02 (patisiran)

Snippet

Sponsor: Alnylam Pharmaceuticals | Conditions: TTR-mediated Amyloidosis | Phase 1 | Status: COMPLETED